223 related articles for article (PubMed ID: 10824925)
21. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
22. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Rubin BP; Singer S; Tsao C; Duensing A; Lux ML; Ruiz R; Hibbard MK; Chen CJ; Xiao S; Tuveson DA; Demetri GD; Fletcher CD; Fletcher JA
Cancer Res; 2001 Nov; 61(22):8118-21. PubMed ID: 11719439
[TBL] [Abstract][Full Text] [Related]
23. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H
J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668
[TBL] [Abstract][Full Text] [Related]
24. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
25. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic targets in gastrointestinal stromal tumors].
Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
[TBL] [Abstract][Full Text] [Related]
28. Keratin 1 expression in endothelia and mesenchymal tumors: an immunohistochemical analysis of normal and neoplastic tissues.
Remotti F; Fetsch JF; Miettinen M
Hum Pathol; 2001 Aug; 32(8):873-9. PubMed ID: 11521233
[TBL] [Abstract][Full Text] [Related]
29. Comparative ultrastructural analysis and KIT/PDGFRA genotype in 125 gastrointestinal stromal tumors.
Agaram NP; Baren A; Arkun K; Dematteo RP; Besmer P; Antonescu CR
Ultrastruct Pathol; 2006; 30(6):443-52. PubMed ID: 17182437
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
[TBL] [Abstract][Full Text] [Related]
31. PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features.
Pauls K; Merkelbach-Bruse S; Thal D; Büttner R; Wardelmann E
Histopathology; 2005 Feb; 46(2):166-75. PubMed ID: 15693889
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course.
Lasota J; Dansonka-Mieszkowska A; Stachura T; Schneider-Stock R; Kallajoki M; Steigen SE; Sarlomo-Rikala M; Boltze C; Kordek R; Roessner A; Stachura J; Miettinen M
Mod Pathol; 2003 Dec; 16(12):1257-64. PubMed ID: 14681327
[TBL] [Abstract][Full Text] [Related]
33. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.
Boldrini L; Ursino S; Gisfredi S; Faviana P; Donati V; Camacci T; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4101-8. PubMed ID: 15217946
[TBL] [Abstract][Full Text] [Related]
34. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.
Hirota S; Nishida T; Isozaki K; Taniguchi M; Nakamura J; Okazaki T; Kitamura Y
J Pathol; 2001 Apr; 193(4):505-10. PubMed ID: 11276010
[TBL] [Abstract][Full Text] [Related]
35. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.
Liegl B; Hornick JL; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Mar; 33(3):437-46. PubMed ID: 19011564
[TBL] [Abstract][Full Text] [Related]
37. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile.
Allander SV; Nupponen NN; Ringnér M; Hostetter G; Maher GW; Goldberger N; Chen Y; Carpten J; Elkahloun AG; Meltzer PS
Cancer Res; 2001 Dec; 61(24):8624-8. PubMed ID: 11751374
[TBL] [Abstract][Full Text] [Related]
39. High-resolution melting amplicon analysis as a method to detect c-kit and platelet-derived growth factor receptor alpha activating mutations in gastrointestinal stromal tumors.
Holden JA; Willmore-Payne C; Coppola D; Garrett CR; Layfield LJ
Am J Clin Pathol; 2007 Aug; 128(2):230-8. PubMed ID: 17638656
[TBL] [Abstract][Full Text] [Related]
40. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.
Miettinen M; Lasota J
Pol J Pathol; 2003; 54(1):3-24. PubMed ID: 12817876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
